Pilot Study Evaluating the Acceptability and Absorption of the Bioactive Compounds of a Russian Tarragon Nutrasorb Bar
Pilot Study Evaluating the Hedonic Acceptability and Absorption of the Bioactive Compounds of a 5011-Nutrasorb Bar (Russian Tarragon Nutrasorb)
2 other identifiers
observational
20
1 country
1
Brief Summary
The purpose of this study is to make a bar from the soy-protein Russian Tarragon complex (PMI-5011/Nutrasorb) that is safe and acceptable for consumption, and to test the blood levels of plasma bioactive (DMC-2) after ingestion of the bar. The PMI-5011/Nutrasorb comes from a plant source called Artemisia dracunculus. This plant has a long history of medicinal (health) and culinary (food) use and has been reported as effective as a traditional treatment for diabetes in various parts of the world.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 6, 2021
CompletedStudy Start
First participant enrolled
October 25, 2021
CompletedFirst Posted
Study publicly available on registry
November 23, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2022
CompletedResults Posted
Study results publicly available
November 18, 2023
CompletedNovember 18, 2023
November 1, 2023
1 year
October 6, 2021
October 24, 2023
November 14, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Palatability of Bar
Participants were asked to rate the bar on a visual analog scale to indicate their impression of its visual appearance, smell, taste, texture, aftertaste, and overall pleasantness. The scale range for each attribute is 0-100 with higher scores equating to a better outcome.
Test Day (immediately after taste-testing the bar)
Secondary Outcomes (3)
Levels of Plasma BIoactive (DMC-2) Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.
10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption
Levels of Serum Glucose Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.
10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption
Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.
10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption
Study Arms (1)
Nutrasorb bar evaluation
Participants in Phase 1 will taste test the bar for acceptability. Participants in Phase 2 will consume the bar and have blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2).
Interventions
250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
Eligibility Criteria
healthy males and females aged 18-50 with a body mass index between 20-30 kg/m2
You may qualify if:
- Healthy males or females between 18 and 50 years of age inclusive.
- Body mass index between 20-30 kg/m2.
You may not qualify if:
- Pregnant or currently lactating.
- Taking any prescription medications.
- Taking any over-the-counter medications that cannot be stopped for test days.
- Allergic to any ingredients contained in the bar.
- Other conditions or situations that would interfere with the study or the participant's safety as determined by the investigators.
- Participants in Phase 1 of the study may not participate in Phase 2 of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
Results Point of Contact
- Title
- Jennifer C Rood, PhD
- Organization
- Pennington Biomedical Research Center
Study Officials
- PRINCIPAL INVESTIGATOR
Jennifer C Rood, Ph.D.
Pennington Biomedical Research Center
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 6, 2021
First Posted
November 23, 2021
Study Start
October 25, 2021
Primary Completion
October 31, 2022
Study Completion
October 31, 2022
Last Updated
November 18, 2023
Results First Posted
November 18, 2023
Record last verified: 2023-11